Many people set a goal to save $1 million for retirement. This amount may or may not be sufficient in today's economy, but it's at least a good start.

AbbVie's Q4 and full-year 2024 earnings surpassed expectations, driven by strong performance from Skyrizi and Rinvoq, despite Humira's revenue decline due to patent expirations. Management's guidan...

AbbVie Inc. reported strong Q4 2024 results, driven by Skyrizi, Rinvoq, neuroscience products, and eye care, and this offset worse-than-expected Humira erosion. 2025 guidance includes $59 billion i...

Today's pre-market activity is positive, with futures in the green across major indexes: the Dow is +110 points at this hour, with the S&P 500 +26 and the Nasdaq leading the way, +158 points. The s...

AbbVie NYSE: ABBV is a high-quality, dividend-growing pharmaceutical company with a robust outlook for growth: now is a good time to load up on shares. Fears of Humira's patent cliff are behind it,...

AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and Rinvoq make up for a steep decline in those of Humira, its flagship rheumatoid arthr...

Reports Full-Year Diluted EPS of $2.39 on a GAAP Basis, a Decrease of 12.1 Percent; Adjusted Diluted EPS of $10.12, a Decrease of 8.9 Percent; These Results Include an Unfavorable Impact of $1.52 P...

When paired with dividend reinvestment, high-yield dividend stocks have demonstrated remarkable outperformance compared to the S&P 500 over holding periods of 20+ years. This outperformance stems f...

AbbVie has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 3.9% yield, as well as bein...

AbbVie is expected to beat Q4 2024 revenue and EPS estimates, with strong performance from Skyrizi, Rinvoq, and neuroscience products offsetting Humira's decline. Management expects a return to "ro...

For income investors, closed-end funds, or CEFs, remain an attractive investment class that covers various asset classes and promises high distributions and reasonable total returns. CEFs are gener...

Per the terms of the deal, AbbVie will use Neomorph's proprietary platform to develop novel drugs targeting oncology and immunology indications.

Pharmaceutical powerhouse AbbVie (ABBV 0.87%) has been a beast since it spun off from Abbott Laboratories in 2012. Over the past decade, the stock has averaged a dividend yield of 3.5% while raisin...

The Dividend Kings underperformed the broad U.S. equity market in 2024, achieving a 5.53% total return compared to the S&P 500's 24.89%. 2024 returns for the Dividend Kings were primarily driven by...

Acquisition adds potential novel oral peptide IL23R inhibitor for psoriasis as well as a peptide synthesis, screening and optimization platform to strengthen AbbVie's pipeline and R&D capabilities ...